[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1986

Etretinate Therapy and Immune Activities

Author Affiliations

Clinical Pharmacology Unit Department of Dermatology University of Michigan Medical Center and Veterans Administration Medical Center 1500 E Medical Center Dr Ann Arbor, MI 48109-0010; Birmingham, Ala

Arch Dermatol. 1986;122(6):629-630. doi:10.1001/archderm.1986.01660180029009

To the Editor.—  In the July 1985 issue of the Archives, we reported reduction of antibody-dependent cell-mediated cytotoxicity (ADCC) of polymorphonuclear leukocytes obtained from patients during etretinate therapy for psoriasis.1 To further examine the immunomodulatory effect of the retinoid, we also monitored natural killing (NK) activity of lymphocytes and ADCC of monocytes obtained from the same study patients, comparing the activities with those of control subjects.Lymphocytes for the NK cell cytotoxicity assay were isolated by collecting nonadherent monocytes after Ficoll-Hypaque density centrifugation. A human myeloid cell line (K562) was used as the target cell. Radioactive labeling of K562 cells by sodium chromate Cr 51 was accomplished as previously described.2 For the assay, lymphocyte effector cells were incubated with the K562 target cells at three effector-to-target ratios (10:1, 5:1, and 2:1). The rest of the assay procedure and calculation of the percent of cytotoxicity were identical to methods

First Page Preview View Large
First page PDF preview
First page PDF preview